Medexus Pharmaceuticals Accepts Metoject® Ruling

Medexus Pharmaceuticals (TSE:MDP) has released an update.

Medexus Pharmaceuticals has announced that it will not appeal the Federal Court’s decision that invalidated the Canadian patent for its drug Metoject®, with company executives expressing confidence that the ruling will not significantly affect their business operations or strategy. The company had been in litigation since August 2020 following the launch of a generic version of the drug. Despite the setback, the leadership at Medexus is optimistic about moving past the litigation and focusing on growing their specialty pharmaceutical business in North America.

For further insights into TSE:MDP stock, check out TipRanks’ Stock Analysis page.